Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer Merck.com FDA OKs New Keytruda Shot for Cancer The New York Times Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications OncLive Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial …
Read More »